These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 36614956)
1. Prognostic Values of METTL3 and Its Roles in Tumor Immune Microenvironment in Pan-Cancer. Guo Y; Heng Y; Chen H; Huang Q; Wu C; Tao L; Zhou L J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614956 [No Abstract] [Full Text] [Related]
2. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker. Zhao C; Liu Y; Ju S; Wang X Int J Gen Med; 2021; 14():7411-7422. PubMed ID: 34744452 [TBL] [Abstract][Full Text] [Related]
3. Systematic pan-cancer analysis of the potential tumor diagnosis and prognosis biomarker P4HA3. Wu Y; Zhang B; Nong J; Rodrìguez RA; Guo W; Liu Y; Zhao S; Wei R Front Genet; 2023; 14():1045061. PubMed ID: 37035741 [No Abstract] [Full Text] [Related]
4. Zhou Y; Guo S; Li Y; Chen F; Wu Y; Xiao Y; An J Front Oncol; 2022; 12():824190. PubMed ID: 35574315 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker. Meng W; Jiang Z; Zhang X; Cai B; Ma L; Guan Y Comput Math Methods Med; 2022; 2022():3119721. PubMed ID: 36466552 [TBL] [Abstract][Full Text] [Related]
6. Multifaceted Roles of the Hu C; Liu J; Li Y; Jiang W; Ji D; Liu W; Ma T Biomolecules; 2022 Jul; 12(8):. PubMed ID: 36008936 [TBL] [Abstract][Full Text] [Related]
7. Integrative proteomics and m6A microarray analyses of the signatures induced by METTL3 reveals prognostically significant in gastric cancer by affecting cellular metabolism. Peng G; Chen S; Zheng N; Tang Y; Su X; Wang J; Dong R; Wu D; Hu M; Zhao Y; Liu M; Wu H Front Oncol; 2022; 12():996329. PubMed ID: 36465351 [TBL] [Abstract][Full Text] [Related]
8. Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker. Liu W; Liu C; You J; Chen Z; Qian C; Lin W; Yu L; Ye L; Zhao L; Zhou R Front Cell Dev Biol; 2022; 10():954214. PubMed ID: 36120577 [No Abstract] [Full Text] [Related]
9. Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets. Zhou Y; Yin Z; Hou B; Yu M; Chen R; Jin H; Jian Z Cancer Manag Res; 2019; 11():3921-3931. PubMed ID: 31118805 [No Abstract] [Full Text] [Related]
10. Identification and Validation of METTL3-Related Molecules for Predicting Prognosis and Efficacy of Immunotherapy in Gastric Cancer Based on m6A Methylome and Transcriptome Sequencing Analysis. Chen S; Su X; Wang J; Zheng N; Tang Y; Peng G; Dong R; Lu F; Liu M; Zhao Y; Wu H Front Oncol; 2022; 12():935239. PubMed ID: 35965524 [TBL] [Abstract][Full Text] [Related]
11. The RNA m Su W; Che L; Liao W; Huang H Front Immunol; 2024; 15():1335774. PubMed ID: 38322265 [TBL] [Abstract][Full Text] [Related]
12. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma. Shen S; Yan J; Zhang Y; Dong Z; Xing J; He Y Ann Transl Med; 2021 Jan; 9(1):59. PubMed ID: 33553352 [TBL] [Abstract][Full Text] [Related]
13. PRAME Is a Potential Carcinogenic Biomarker that Correlates with Patient Prognosis and Tumor Immunity Based on Pan-Cancer Analysis. Zhao Q; Zhang Z; Wu Y Ann Clin Lab Sci; 2022 Mar; 52(2):185-195. PubMed ID: 35414497 [TBL] [Abstract][Full Text] [Related]
14. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers. Wang N; Zhu L; Wang L; Shen Z; Huang X Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736 [TBL] [Abstract][Full Text] [Related]
15. Methyltransferase-like 3 Modulates Severe Acute Respiratory Syndrome Coronavirus-2 RNA N6-Methyladenosine Modification and Replication. Zhang X; Hao H; Ma L; Zhang Y; Hu X; Chen Z; Liu D; Yuan J; Hu Z; Guan W mBio; 2021 Aug; 12(4):e0106721. PubMed ID: 34225491 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive Pan-Cancer Analysis Confirmed That ATG5 Promoted the Maintenance of Tumor Metabolism and the Occurrence of Tumor Immune Escape. Xu C; Zang Y; Zhao Y; Cui W; Zhang H; Zhu Y; Xu M Front Oncol; 2021; 11():652211. PubMed ID: 33842365 [TBL] [Abstract][Full Text] [Related]
17. METTL3 facilitates tumor progression via an m Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive Pan-Cancer Analysis of the Prognostic and Immunological Roles of the METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C Axis. Jiang X; Yuan Y; Tang L; Wang J; Liu Q; Zou X; Duan L Front Cell Dev Biol; 2021; 9():765772. PubMed ID: 34858987 [TBL] [Abstract][Full Text] [Related]
19. Cyclin-Dependent Kinase 6 Identified as the Target Protein in the Antitumor Activity of Wei C; Zhao Y; Ji T; Sun Y; Cai X; Peng X Front Oncol; 2022; 12():865409. PubMed ID: 35480115 [TBL] [Abstract][Full Text] [Related]
20. Identification of METTL3 as an Adverse Prognostic Biomarker in Hepatocellular Carcinoma. Liu GM; Zeng HD; Zhang CY; Xu JW Dig Dis Sci; 2021 Apr; 66(4):1110-1126. PubMed ID: 32333311 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]